Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all‐oral direct antiviral therapy-Reference-Cited by-同舟云学术

Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all‐oral direct antiviral therapy

Published:2020-04 Issue:4 Volume:50 Page:453-465
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Mawatari Seiichi¹^ORCID,Oda Kohei¹,Kumagai Kotaro¹,Tabu Kazuaki¹,Ijuin Sho¹,Fujisaki Kunio²,Inada Yukiko³,Uto Hirofumi¹³,Saisyoji Akiko¹⁴,Hiramine Yasunari⁴,Hori Takeshi⁵,Taniyama Ohki¹,Toyodome Ai¹,Sakae Haruka¹,Hashiguchi Masafumi¹⁵,Kure Takeshi¹⁶,Sakurai Kazuhiro⁶,Tamai Tsutomu¹⁵,Moriuchi Akihiro¹⁶,Ido Akio¹

Affiliation:

1. Digestive and Lifestyle Diseases, Department of Human and Environmental SciencesKagoshima University Graduate School of Medical and Dental Sciences Kagoshima Japan

2. Department of Hepatology, Kirishima Medical Center Kagoshima Japan

3. Center for Digestive and Liver Diseases,Miyazaki Medical Center Hospital Miyazaki Japan

4. Department of Hepatology, Kagoshima Kouseiren Hospital Kagoshima Japan

5. Department of Gastroenterology and HepatologyKagoshima City Hospital Kagoshima Japan

6. Department of GastroenterologyNational Hospital Organization Kagoshima Medical Center Kagoshima Japan

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13474

Reference49 articles.

1. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

2. A Novel Simple Assay System to Quantify the Percent HCV-RNA Levels of NS5A Y93H Mutant Strains and Y93 Wild-Type Strains Relative to the Total HCV-RNA Levels to Determine the Indication for Antiviral Therapy with NS5A Inhibitors

3. New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir

4. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea;Clinical and Molecular Hepatology;2023-04-01

2. Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?;Viruses;2022-01-06

3. Safety and efficacy of glecaprevir and pibrentasvir in north Tohoku Japanese patients with genotype 1/2 hepatitis C virus infection;Health Science Reports;2022-01

4. Host-Targeting Antivirals for Treatment of Hepatitis C;Advances in Hepatology;2021-07-28

5. Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir;Internal Medicine;2021